4-hydroxy-5,6-dihydropyrones .2. Potent non-peptide inhibitors of HIV protease

被引:60
|
作者
Tait, BD
Hagen, S
Domagala, J
Ellsworth, EL
Gajda, C
Hamilton, HW
Prasad, JVNV
Ferguson, D
Graham, N
Hupe, D
Nouhan, C
Tummino, PJ
Humblet, C
Lunney, EA
Pavlovsky, A
Rubin, J
Gracheck, SJ
Baldwin, ET
Bhat, TN
Erickson, JW
Gulnik, SV
Liu, BS
机构
[1] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOCHEM, ANN ARBOR, MI 48105 USA
[2] WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT BIOMOL STRUCT & DRUG DESIGN, ANN ARBOR, MI 48105 USA
[3] NCI, FREDERICK CANC RES & DEV CTR,DYNCORP,PRI, STRUCT BIOCHEM PROGRAM, FREDERICK, MD 21702 USA
关键词
D O I
10.1021/jm970615f
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The 4-hydroxy-5,6-dihydropyrone template was utilized as a flexible scaffolding from which to build potent active site inhibitors of HIV protease. Dihydropyrone Ic (5,6-dihydro-4-hydroxy-6-phenyl-3-[(2-phenylethyl)thio]-2H-pyran-2-one) was modeled in the active site of HIV protease utilizing a similar binding mode found for the previously reported 4-hydroxybenzopyran-2-ones. Our model led us to pursue the synthesis of 6,6-disubstituted dihydropyrones with the aim of filling S-1 and S-2 and thereby increasing the potency of the parent dihydropyrone Ic which did not fill S-2. Toward this end we attached various hydrophobic and hydrophilic side chains at the 6-position of the dihydropyrone to mimic the natural and unnatural amino acids known to be effective substrates at P-2 and P-2'. Parent dihydropyrone Ic (IC50 = 2100 nM) was elaborated into compounds with greater than a 100-fold increase in potency [18c, IC50 = 5 nM, 5-(3,6-dihydroxy-6-hydroxy-6-oxo-2-phenyl-5-[2-phenylethyl)thio]-2H-pyran-2-yl)pentanoic acid and 12c, IC50 = 51 nM, 5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)thio]-2H-pyran-2-one]. Optimization of the 3-position fragment to fill S-1' and S-2' afforded potent HIV protease inhibitor 49 [IC50 = 10 nM, 3-[(2-tert-butyl-5-methylphenyl)sulfanyl]-5,6-dihydro-4-hydroxy-6-phenyl-6-(2-phenylethyl)-2H-pyran-2-one]. The resulting low molecular weight compounds (<475) have one or no chiral centers and are readily synthesized.
引用
收藏
页码:3781 / 3792
页数:12
相关论文
共 50 条
  • [21] Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors
    Thaisrivongs, S
    Skulnick, HI
    Turner, SR
    Strohbach, JW
    Tommasi, RA
    Johnson, PD
    Aristoff, PA
    Judge, TM
    Gammill, RB
    Morris, JK
    Romines, KR
    Chrusciel, RA
    Hinshaw, RR
    Chong, KT
    Tarpley, WG
    Poppe, SM
    Slade, DE
    Lynn, JC
    Horng, MM
    Tomich, PK
    Seest, EP
    Dolak, LA
    Howe, WJ
    Howard, GM
    Schwende, FJ
    Toth, LN
    Padbury, GE
    Wilson, GJ
    Shiou, LH
    Zipp, GL
    Wilkinson, KF
    Rush, BD
    Ruwart, MJ
    Koeplinger, KA
    Zhao, ZY
    Cole, S
    Zaya, RM
    Kakuk, TJ
    Janakiraman, MN
    Watenpaugh, KD
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (22) : 4349 - 4353
  • [22] NOVEL AZA-CYCLIC UREAS THAT ARE POTENT INHIBITORS OF HIV PROTEASE .2.
    STEWART, KD
    PARK, CH
    KONG, XP
    SHAM, HL
    ZHAO, C
    HERRIN, T
    BETEBENNER, DA
    ROSENBROOK, W
    MADIGAN, D
    LIN, SQ
    SALDIVAR, A
    WIDEBURG, NE
    KEMPF, DJ
    NORBECK, DW
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 8 - MEDI
  • [23] The design and synthesis of non-peptide peptidomimetic inhibitors of the HIV-1 protease. Evidence for improved transport.
    Smith, AB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 11 - COMP
  • [24] Non-peptidic HIV protease inhibitors:: C2-symmetry-based design of bis-sulfonamide dihydropyrones
    Janakiraman, MN
    Watenpaugh, KD
    Tomich, PK
    Chong, KT
    Turner, SR
    Tommasi, RA
    Thaisrivongs, S
    Strohbach, JW
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (10) : 1237 - 1242
  • [25] Structure-based design of novel HIV protease inhibitors: Sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors
    Thaisrivongs, S
    Janakiraman, MN
    Chong, KT
    Tomich, PK
    Dolak, LA
    Turner, SR
    Strohbach, JW
    Lynn, JC
    Horng, MM
    Hinshaw, RR
    Watenpaugh, KD
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (12) : 2400 - 2410
  • [26] QSAR study on 5,6-dihydropyran-7-ones for the discovery of potent non-peptidic inhibitors of HIV protease
    Srivastava, A. K.
    Varma, A.
    OXIDATION COMMUNICATIONS, 2006, 29 (03): : 545 - 554
  • [27] 5,6-dihydropyran-2-ones possessing various sulfonyl functionalities: Potent nonpeptidic inhibitors of HIV protease
    Boyer, FE
    Prasad, JVNV
    Domagala, JM
    Ellsworth, EL
    Gajda, C
    Hagen, SE
    Markoski, LJ
    Tait, BD
    Lunney, EA
    Palovsky, A
    Ferguson, D
    Graham, N
    Holler, T
    Hupe, D
    Nouhan, C
    Tummino, PJ
    Urumov, A
    Zeikus, E
    Zeikus, G
    Gracheck, SJ
    Sanders, JM
    VanderRoest, S
    Brodfuehrer, J
    Iyer, K
    Sinz, M
    Gulnik, SV
    Erickson, JW
    JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (05) : 843 - 858
  • [28] Non-peptide inhibitors of HIV-1 protease. Synthesis and structural evaluation of symmetric and non-symmetric naphthalenesulfonic acid analogues
    Wong, MF
    Huang, PP
    Brinkworth, RI
    Yashiro, M
    Mohan, P
    Fairlie, DP
    Baba, M
    Verma, S
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1996, 31 (03) : 249 - 255
  • [29] Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: The profound effect of polarity on antiviral activity
    Hagen, SE
    Prasad, JVNV
    Boyer, FE
    Domagala, JM
    Ellsworth, EL
    Gajda, C
    Hamilton, HW
    Markoski, LJ
    Steinbaugh, BA
    Tait, BD
    Lunney, EA
    Tummino, PJ
    Ferguson, D
    Hupe, D
    Nouhan, C
    Gracheck, SJ
    Saunders, JM
    VanderRoest, S
    JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (23) : 3707 - 3711
  • [30] STRUCTURE-BASED DESIGN OF NOVEL HIV PROTEASE INHIBITORS - CARBOXAMIDE-CONTAINING 4-HYDROXYCOUMARINS AND 4-HYDROXY-2-PYRONES AS POTENT NONPEPTIDIC INHIBITORS
    THAISRIVONGS, S
    WATENPAUGH, KD
    HOWE, WJ
    TOMICH, PK
    DOLAK, LA
    CHONG, KT
    TOMICH, CSC
    TOMASSELLI, AG
    TURNER, SR
    STROHBACH, JW
    MULICHAK, AM
    JANAKIRAMAN, MN
    MOON, JB
    LYNN, JC
    HORNG, MM
    HINSHAW, RR
    CURRY, KA
    ROTHROCK, DJ
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (18) : 3624 - 3637